Pfizer’s Talzenna (talazoparib) Receives European Commission Approval for Germline BRCA-Mutated Locally Advanced or Metastatic Breast Cancer

 Pfizer’s Talzenna (talazoparib) Receives European Commission Approval for Germline BRCA-Mutated Locally Advanced or Metastatic Breast Cancer

Pfizer’s Talzenna (talazoparib) Receives European Commission Approval for Germline BRCA-Mutated Locally Advanced or Metastatic Breast Cancer

Shots:

  • The approval is based on P-III EMBRACA study results assessing Talzenna (qd, 1mg) vs CT (capecitabine/eribulin/gemcitabine/vinorelbine) in 431 patients in ratio (2:1) with inherited BRCA1/2 mutation & LA or m-triple-negative or HR+/HER2- breast cancer, prior treated with 3L CT regimen
  • The P-III EMBRACA study results: mPFS (8.6 mos.vs 5.6mos.); ORR (62.6% vs 27.2%); 46% reduction in the risk of disease progression
  • Talzenna is a PARP inhibitor, being evaluated in multiple studies for breast and other cancers, including early triple-negative breast cancer and prostate cancer and has received FDA’s approval for gBRCAm HER2-, LA or m-breast cancer

Click here to read full press release/ article | Ref: Pfizer | Image: Q Costa Rica

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post